User:Mr. Ibrahem/Regorafenib

Mr. Ibrahem/Regorafenib
Clinical data
Trade names	Stivarga, Regonix
Other names	BAY 73-4506
AHFS/Drugs.com	Monograph
MedlinePlus	a613004
License data	EU EMA: by INN; US DailyMed: Regorafenib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Protein kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	69-83%
Protein binding	99.5%
Metabolism	Hepatic (UGT1A9-mediated)
Elimination half-life	20-30 hours
Excretion	Feces (71%), urine (19%)
Identifiers
	IUPAC name 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide hydrate;
Chemical and physical data
Formula	C21H15ClF4N4O3
Molar mass	482.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl;
	InChI InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32); Key:FNHKPVJBJVTLMP-UHFFFAOYSA-N;

Regorafenib, sold under the brand name Stivarga among others, is a medication used to treat colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular cancer.^[2] It is used after other treatments have failed.^[2] It is taken by mouth.^[2]

Common side effects include pain, tiredness, rash, diarrhea, infection, and high blood pressure.^[1] Other side effects may include liver problems, bleeding, and gastrointestinal perforation.^[1] It is a protein kinase inhibitor including the VEGF receptors and FGF receptors.^[1]^[2]

Regorafenib was approved for medical use in the United States in 2012 and Europe in 2013.^[2]^[1] In the United Kingdom 4 weeks of treatment costs the NHS about £3,750 as of 2021.^[3] In the United States this amount costs about 19,600 USD.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f "Stivarga". Archived from the original on 6 March 2021. Retrieved 16 October 2021.
^ ^a ^b ^c ^d ^e ^f "Regorafenib Monograph for Professionals". Drugs.com. Archived from the original on 20 September 2020. Retrieved 16 October 2021.
^ ^a ^b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1053. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ "Stivarga Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 6 March 2016. Retrieved 16 October 2021.

[EPAR2021-1] ^ ^a ^b ^c ^d ^e ^f "Stivarga". Archived from the original on 6 March 2021. Retrieved 16 October 2021.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f "Regorafenib Monograph for Professionals". Drugs.com. Archived from the original on 20 September 2020. Retrieved 16 October 2021.

[BNF80-3] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1053. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[4] "Stivarga Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 6 March 2016. Retrieved 16 October 2021.

[1]

[2]

[3]

[4]